$23.89
+2.0%Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Wall Street analysts project that AZTA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 44.50, with estimates ranging from a low of 44.00 to a high of 45.00.
The consensus 1-year price target stands at 44.50, with estimates ranging from a low of 44.00 to a high of 45.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Limited coverage may indicate reduced institutional interest or information availability.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
During the last 12 months, insiders have purchased $234K and sold $133K worth of AZTA shares, resulting in $101K of net buying activity.
10.0K
163.80K
0
0.00
+164K
+$164K
0
0.00
0
0.00
+0
+$0
0
0.00
316
9.29K
-9K
-$9K
2.5K
69.90K
4.3K
123.86K
-54K
-$54K
Cornog William L
Director
$164K
Lin Lawrence Y.
Officer: Evp, Cfo And Treasurer
$70K
Zhou Ginger
Officer: Svp And Gm, Multiomics
$62K
Pirogova Olga
Officer: Svp And Chro
$62K
Marotta John
Director, Officer: President And Ceo
$9K
Moderately bullish with $101K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
3 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Sustained buying momentum: Consistent net buying over multiple quarters suggests insiders maintain conviction in the company's prospects. This is particularly meaningful if buying continued through market volatility.
Continue your AZTA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.